Remimazolam Tosilate for injection + Propofol Injection
Phase 2/3Recruiting 3 views this week 0 watching⚡ Active
Interest: 45/100
45
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Operative Sedation of Pediatric
Conditions
Operative Sedation of Pediatric, Operative Sedation of Adolescent Patients
Trial Timeline
Jul 10, 2025 → May 1, 2026
NCT ID
NCT07036419About Remimazolam Tosilate for injection + Propofol Injection
Remimazolam Tosilate for injection + Propofol Injection is a phase 2/3 stage product being developed by Jiangsu Hengrui Medicine for Operative Sedation of Pediatric. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07036419. Target conditions include Operative Sedation of Pediatric, Operative Sedation of Adolescent Patients.
What happened to similar drugs?
20 of 20 similar drugs in Operative Sedation of Pediatric were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
15
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07036419 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Operative Sedation of Pediatric